NasdaqGS:ILMNLife Sciences
Is Illumina’s (ILMN) TruPath Rare Disease Push Reframing Its Clinical Sequencing Investment Narrative?
In late February 2026, Illumina, Inc. launched its TruPath Genome whole‑genome workflow and expanded Illumina Laboratory Services to support Florida State University’s new pediatric rare disease diagnostic lab with clinical sequencing and interpretation.
Together, these moves pair higher‑resolution sequencing technology with real‑world clinical deployment, underscoring Illumina’s push to make advanced rare disease diagnostics more accessible and operationally efficient for hospitals and...